Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2018 (2018), Article ID 2170484, 5 pages
https://doi.org/10.1155/2018/2170484
Case Report

Posaconazole-Induced Adrenal Insufficiency in a Case of Chronic Myelomonocytic Leukemia

1Department of Medicine, University of Maryland Medical Center, Baltimore, MD, USA
2Department of Medicine, Division of Endocrinology, Diabetes and Nutrition, University of Maryland Medical Center, Baltimore, MD, USA

Correspondence should be addressed to Rana Malek

Received 16 October 2017; Revised 7 December 2017; Accepted 18 December 2017; Published 16 January 2018

Academic Editor: Osamu Isozaki

Copyright © 2018 Ann Miller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Arlt, “The approach to the adult with newly diagnosed adrenal insufficiency,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 4, pp. 1059–1067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Sonino, “The use of ketoconazole as an inhibitor of steroid production,” The New England Journal of Medicine, vol. 317, no. 13, pp. 812–818, 1987. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Pivonello, M. De Leo, A. Cozzolino, and A. Colao, “The treatment of Cushing's disease,” Endocrine Reviews, vol. 36, no. 4, pp. 385–486, 2015. View at Publisher · View at Google Scholar
  4. F. Castinetti, L. Guignat, P. Giraud et al., “Ketoconazole in Cushing's disease: is it worth a try?” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 5, pp. 1623–1630, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Moncet, D. J. Morando, F. Pitoia, S. B. Katz, M. A. Rossi, and O. D. Bruno, “Ketoconazole therapy: An efficacaious alternative to achieve eucortisolism in patients with Cushing's syndrome,” Medicina, vol. 67, no. 1, pp. 26–31, 2007. View at Google Scholar · View at Scopus
  6. FDA Drug Safety Communication, “FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems,” 2017(4/15), 2013.
  7. S. Langner, P. B. Staber, and P. Neumeister, “Posaconazole in the management of refractory invasive fungal infections,” Therapeutics and Clinical Risk Management, vol. 4, no. 4, pp. 747–757, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. G. Albert, M. J. DeLeon, and A. B. Silverberg, “Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients,” Critical Care Medicine, vol. 29, no. 3, pp. 668–670, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S. G. Santhana Krishnan and R. K. Cobbs, “Reversible acute adrenal insufficiency caused by fluconazole in a critically ill patient.,” Postgraduate Medical Journal, vol. 82, no. 971, p. e23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. W. C. Hoover, L. J. Britton, J. Gardner, T. Jackson, and H. Gutierrez, “Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3a4 inhibitor,” Annals of Pharmacotherapy, vol. 45, no. 7-8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. St Clair and J. D. Maguire, “Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency,” International Journal of STD & AIDS, vol. 23, no. 5, pp. 371-372, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Shibata, M. Kami, Y. Kanda et al., “Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide,” American Journal of Hematology, vol. 66, no. 4, pp. 303–305, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. M.-C. Blondin, H. Beauregard, and O. Serri, “Iatrogenic cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: Two cases and literature review,” Endocrine Practice, vol. 19, no. 6, pp. e138–e141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Bolland, W. Bagg, M. G. Thomas, J. A. Lucas, R. Ticehurst, and P. N. Black, “Cushing's Syndrome Due to Interaction between Inhaled Corticosteroids and Itraconazole,” Annals of Pharmacotherapy, vol. 38, no. 1, pp. 46–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Skov, K. M. Main, I. B. Sillesen, J. Müller, C. Koch, and S. Lanng, “Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide,” European Respiratory Journal, vol. 20, no. 1, pp. 127–133, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. A. K. Duman and P. P. Fulco, “Adrenal insufficiency with voriconazole and inhaled/intranasal corticosteroids: case report and systematic review,” Journal of Pharmacy Practice, vol. 30, no. 4, pp. 459–463, 2017. View at Publisher · View at Google Scholar
  17. J. Snaith, K. Burns, J. Kok, S. Chen, and N. W. Cheung, “A case of rhino-orbital mucormycosis in diabetes with haematogenous cerebral spread,” Medical Mycology Case Reports, vol. 13, pp. 22–24, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. A. F. Turcu and R. J. Auchus, “Adrenal Steroidogenesis and Congenital Adrenal Hyperplasia,” Endocrinology and Metabolism Clinics of North America, vol. 44, no. 2, pp. 275–296, 2015. View at Publisher · View at Google Scholar · View at Scopus